Codon optimization for titer and fidelity improvement

Patent metadata

Field	Value
Publication number	US-10487133-B2
Application number	US-201515537290-A
Country	US
Kind code	B2
Filing date	Dec 18, 2015
Priority date	Dec 19, 2014
Publication date	Nov 26, 2019
Grant date	Nov 26, 2019

Abstract

The invention provides methods for producing a protein in a cell free protein synthesis system such that the protein does not contain an asparagine (Asn or N) residue at serine (Ser or S) positions. Also provided are compositions and nucleic acid templates for use in the methods described herein.

First claim

What is claimed is:

1. A method for producing a full-length protein of interest in a cell free protein synthesis system said protein having multiple serine residues, the method comprising the steps of:
i) combining a nucleic acid template encoding the full-length protein with a cell free protein synthesis system;
wherein the template comprises codons encoding serine residues,
wherein the template has been modified such that no more than 10% of the codons encoding serine residues are AGC,
wherein at least one of the codons encoding serine residues in the template is AGT, TCA, or TCG; and
ii) incubating the template and the cell free protein synthesis system under conditions permitting the translation of the protein of interest.

2. The method of claim 1 , wherein the cell free protein synthesis system is derived from a bacterial cell.

3. The method of claim 2 , wherein the bacterial cell is an E. coli cell.

4. The method of claim 1 , wherein the cell free protein synthesis system has an active oxidative phosphorylation system.

5. The method of claim 1 , wherein the protein of interest is an antibody or a fragment thereof.

6. The method of claim 5 , wherein the antibody is IgG or IgE.

7. The method of claim 1 , wherein the protein of interest is produced at a concentration of greater than 6 mg/liter.

8. The method of claim 1 , wherein the protein of interest comprises amino acids wherein more than 15% of the amino acids are serine residues.

9. The method of claim 1 , wherein the codons encoding serine residues are selected from the group comprising of AGT, TCA, TCC, TCG and TCT.

10. The method of claim 1 , wherein the nucleic acid template has no AGC codons.

11. The method of claim 10 , wherein the nucleic acid template has no AGT codons.

12. A combination of a nucleic acid template and a cell free protein synthesis system for producing a protein of interest having a plurality of serine residues, the combination comprising:
a nucleic acid template encoding the protein of interest, wherein the nucleic acid template comprises codons encoding serine residues and wherein no more than 10% of the codons encoding the serine residues are AGC; and
a cell free protein synthesis system.

13. The combination of claim 12 , wherein the cell free protein synthesis system is derived from a bacterial cell.

14. The combination of claim 13 , wherein the bacterial cell is an E. coli cell.

15. The combination of claim 12 , wherein the cell free protein synthesis system has an active oxidative phosphorylation system.

16. The combination of claim 12 , wherein the protein of interest is an antibody or a fragment thereof.

17. The combination of claim 16 , wherein the antibody is IgG or IgE.

18. The combination of claim 12 , wherein the protein of interest is produced at a concentration of greater than 6 mg/liter.

19. The combination of claim 12 , wherein the protein of interest comprises amino acids wherein more than 15% of the amino acids are serine residues.

20. The combination of claim 12 , wherein the codons encoding the serine residues are selected from the group comprising of AGT, TCA, TCC, TCG and TCT.

21. The combination of claim 12 , wherein the nucleic acid template has no AGC codons.

22. The combination of claim 21 , wherein the nucleic acid template has no AGT codons.

23. A nucleic acid encoding a full-length protein of interest having a plurality of serine residues,
wherein the nucleic acid has been modified such that no more than 10% of the codons encoding the serine residues are AGC, and
wherein at least one of the codons encoding serine residues in the nucleic acid is AGT, TCA, or TCG.

24. The nucleic acid of claim 23 , wherein the protein of interest is an antibody.

25. The nucleic acid of claim 23 , wherein the protein of interest comprises amino acids wherein more than 15% of the amino acids are serine residues.

26. The nucleic acid of claim 23 , wherein the codons encoding serine residues are selected from the group consisting of AGT, TCA, TCC, TCG and TCT.

Assignees

• Sutro Biopharma Inc

Inventors

• Yin Gang

Classifications

• C07K1/003

  by transforming the C-terminal amino acid to amides · CPC title

• C12N15/67

  General methods for enhancing the expression · CPC title

• C07K1/006

  of peptides containing derivatised side chain amino acids · CPC title

• C07K1/02 Primary

  in solution {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12P21/02

  having a known sequence of two or more amino acids, e.g. glutathione · CPC title